New therapeutic options for Alport syndrome

Nephrol Dial Transplant. 2019 Aug 1;34(8):1272-1279. doi: 10.1093/ndt/gfz131.


Alport syndrome (AS) is the most frequent inherited kidney disease after autosomal dominant polycystic kidney disease. It has three different patterns of inheritance-autosomal dominant, autosomal recessive and X-linked-which in part explains the wide spectrum of disease, ranging from isolated microhaematuria to end-stage renal disease early in life. The search for a treatment for AS is being pursued vigorously, not only because of the obvious unmet need but also because AS is a rare disease and any drug approved will have an orphan drug designation with its various benefits. Moreover, AS patients are quite young with very few comorbidities, which facilitates clinical trials. This review identifies the particularities of each pattern of inheritance but focuses mainly on new drugs or therapeutic targets for the disease. Most treatment-related investigations are directed not at the main abnormality in AS, namely collagen IV composition, but rather at the associated inflammation and fibrosis. Thus, AS may serve as a proof of concept for numerous drugs of potential value in many diseases that cause chronic kidney disease.

Keywords: Alport; X linked; autosomal; therapy; treatment.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Fibrosis / prevention & control
  • Genetic Predisposition to Disease
  • Humans
  • Inflammation / prevention & control
  • Nephritis, Hereditary / genetics
  • Nephritis, Hereditary / pathology
  • Nephritis, Hereditary / therapy*
  • Pharmaceutical Preparations / administration & dosage*
  • Stem Cell Transplantation / methods*


  • Anti-Inflammatory Agents
  • Pharmaceutical Preparations